Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 223

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy

De Rycke, Leen, Kruithof, Elli, Van Damme, Nancy, Hoffman, Ilse E. A., Van den Bossche, Nancy, Van den Bosch, Filip, Veys, Eric M., De Keyser, Filip·2003·Arthritis & Rheumatism

Abstract

Objective: To investigate the effect of infliximab treatment on antinuclear antibodies (ANAs), anti–double‐stranded DNA (anti‐dsDNA), antinucleosome, antihistone, and anti–extractable nuclear antigen (anti‐ENA) antibodies in rheumatoid arthritis (RA) and spondylarthropathy (SpA) patients. Methods: Sera from 62 RA and 35 SpA patients treated with infliximab were tested at baseline and week 30 (RA group) or week 34 (SpA group). ANAs were tested by indirect immunofluorescence (IIF) on HEp‐2 cells. Anti‐dsDNA antibodies were detected by IIF on Crithidia luciliae and by enzyme‐linked immunosorbent assay (ELISA) and were further isotyped with γ, μ, and α chain–specific conjugates at various time points. Antinucleosome antibodies were tested by ELISA. Antihistone and anti‐ENA antibodies were detected by line immunoassay. Results: Initially, 32 of 62 RA patients and 6 of 35 SpA patients tested positive for ANAs. After infliximab treatment, these numbers shifted to 51 of 62 (P < 0.001) and 31 of 35 (P < 0.001), respectively. At baseline, none of the RA or SpA patients had anti‐dsDNA antibodies. After infliximab treatment, 7 RA patients (P = 0.016) and 6 SpA patients (P = 0.031) became positive for anti‐dsDNA antibodies. All 7 anti‐dsDNA–positive RA patients had IgM and IgA anti‐dsDNA antibodies. Three of the 6 anti‐dsDNA–positive SpA patients had IgM and IgA anti‐dsDNA antibodies, and 2 had IgM anti‐dsDNA antibodies alone. In both diseases, the IgM anti‐dsDNA antibodies appeared before the IgA anti‐dsDNA antibodies. During the observation period, no IgG anti‐dsDNA antibodies or lupus symptoms were observed. The development of antinucleosome, antihistone, or anti‐ENA antibodies following infliximab treatment was observed in some patients, but the numbers were not statistically significant. Conclusion: Infliximab treatment may induce ANAs, and especially IgM and IgA anti‐dsDNA antibodies, in RA and SpA patients. However, no anti‐dsDNA IgG antibodies or lupus symptoms were observed during the period of observation in this study, and the development of antinucleosome, antihistone, or anti‐ENA antibodies was not statistically significant. These observations do not exclude potential induction of clinically significant lupus in the long term, and further followup is therefore mandatory.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.10876

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 223

Metadata

Authors
De Rycke, L., Kruithof, E., Van Damme, N., Hoffman, I. E. A., Van den Bossche, N., Van den Bosch, F., Veys, E. M., & De Keyser, F.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2003-04
Volume
48
Issue
4
Pages
1015-1023
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2168626353
Cited by
223
References
2
FWCI
18.60
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. https://app.cochat.ai/papers/10.1002/art.10876
The paper
De Rycke, L., Kruithof, E., Van Damme, N., Hoffman, I. E. A., Van den Bossche, N., Van den Bosch, F., Veys, E. M., & De Keyser, F. (2003). Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis & Rheumatism. https://doi.org/10.1002/art.10876

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.